Theleme Partners "have an estimated US$908 million stake in Moderna, the covid-vaccine maker.

Rishi Sunak, then Chancellor of the Exchequer, signed off on spending tens of billions on covid vaccines … never admitted he could profit from the contracts"

What a web of financial shennanigans and incestuous relationships with all the usual suspects.

So Rishi Sunak, is one of the main investors in Theleme Partners.

https://wallmine.com/fund/2r5/theleme-partners-llp

Who have an estimated US$908 million stake in Moderna.

Which is a lot of money invested in a company that had when they initially invested in the company there had been ZERO products to market, ZERO track record of making anything and one contract with the US’s DoD/DARPA.

https://www.wikispooks.com/wiki/Moderna

And other large investors include Blackrock and Vanguard - no surprise they have their sticky mitts in the pie is it? AstraZeneca were also involved with them prior to the IPO:

https://www.businessinsider.com/biggest-investors-in-moderna-before-initial-public-offering-2018-11?op=1&r=US&IR=T

And another give away that mRNA changes DNA/RNA is in the company’s name - ModeRNA - ““named from the combined terms "modified" and "RNA" that just happens to contain "modern"“

https://en.wikipedia.org/wiki/Moderna

And you know Rishi Sunak, who was the then Chancellor of the Exchequer, the person who signed off on the spending tens of billions of GBPs on covid vaccines, never admitted beforehand he could profit from some of the contracts.

ModeRNA is also not a good place to work from this account:

https://www.statnews.com/2016/09/13/moderna-therapeutics-biotech-mrna/

And this is no surprise is it?

Moderna's CEO Stéphane Bancel was selected a Young Global Leader by the World Economic Forum in 2009. He appears quite a bit when searching the WEF website:

https://www.weforum.org/search?query=bancel

Add in the Bill and Melinda Gates Foundation, GAVI, CEPI GSK etc etc connections and it’s no surprise that they had so many high profile investors.

But with an attitude like Bancel’s is it no wonder that his company’s products are not fit for purpose:

“Messenger RNA is like software,”

“If it works in one disease, it should work for thousands.”

Most biotech startups focus on one or two leading drug candidates at first, pushing them through human trials before turning to another target. Moderna, by contrast, has nearly 100 projects going at once. With mRNA, “you can just turn the crank and get a lot of products going into development,” Bancel explained, flashing a smile as though he himself was bemused by the idea’s simplicity.

https://awkwardgit.substack.com/p/theleme-partners-moderna-and-rishi